



## Focus on the antibiotics market

Zurich, July 2017

The antibiotics market is expected to reach USD 57.0 billion by 2024. Rising prevalence of infectious diseases is contributing to the market growth, especially in developing regions such as Asia-Pacific. However, raising capital for companies active in this field has been difficult for the past few years. Thus, Venture Valuation has collected some important facts, figures, and background information about antibiotics financing, including key investors, the biggest financing rounds, and financing trends.



For the period of 2012-2017, we see an increase in the aggregate amount of private financing for antibiotics companies. With still seven months ahead, it looks like 2017 is on its way to becoming the best year for antibiotics financing since 2012. The growth in investment could be explained by the increasing awareness in the market of better antibiotic therapeutics and diagnostics.



As we can see from the graph above, for the period 2012-2016, the USA, Austria, Germany, Ireland, and the United Kingdom were the top five countries for private antibiotics financing. With a grand total of USD 329 million in investment across this period, American companies received more financing than the remaining four market leading countries combined.

Below, you can find the top ten financing rounds in antibiotics companies since 2010, including the investors. As can be seen from the table, the most active investors in antibiotics companies were OrbiMed (USA), Frazier Healthcare Partners (USA), New Leaf Venture Partners (USA), Canaan Partners (USA), and Sofinnova Ventures (Europe/USA).

### **Find investors in antibiotics**

Biotechgate.com offers a professional database containing all the needed information about the investors in the biotech industry. In our unique Biotechgate Investors database, you will find over 3,500 dedicated life sciences investors with contact details and exact specifications of what each investor is looking for. Find your ideal investor in the antibiotics field using Biotechgate.

In our Biotechgate Investors database, there are 875 investors interested in the antibiotic space of which 720 are interested in private companies. Around 20% allocate below a million USD, around 28% invest between one and five million USD, and around 16% invest five to ten million USD, and another 16% each between ten to twenty million USD, and above twenty million USD. A total of 50% are U.S. investors, 22% are from Europe, and 20% are from Asia/Pacific. A total of 25% are focused on Western Europe, 50% are focused on the United States, and 22% have a global focus for their investments.

### **Antibiotics market overview**

In our global Biotechgate Database, we have over 600 antibiotics and other anti-infective companies listed with categorization, contact details, and English company descriptions. With a subscription to Biotechgate, you get access to a growing antibiotics database and also to a global database with over 45,000 companies.

Company Name	Investors	Amount (in million USD)	Country	Date
Nabriva Therapeutics AG	9 key investors (for Biotechgate subscribers only)	120.00	Austria	07-Apr-15
AiCuris Anti-infective Cures GmbH	Santo Holding	73.94	Germany	14-Apr-10
Iterum Therapeutics Ltd.	9 key investors (for Biotechgate subscribers only)	65.00	Ireland	08-May-17
MicuRx	GP TMT Capital Delin Capital 3E Bioventure GP Healthcare Capital	55.00	USA	26-Sep-16
Spero therapeutics	5 key investors (for Biotechgate subscribers only)	51.70	USA	09-Mar-17
Entasis Therapeutics	5 key investors (for Biotechgate subscribers only)	50.00	USA	04-Apr-16
Tetrphase Pharmaceuticals, Inc.	Excel Venture Management CMEA Ventures Fidelity Biosciences Flagship Ventures Mediphase Venture Partners Skyline Ventures	45.00	USA	01-Jun-10
Zavante Therapeutics, Inc.	2 key investors (for Biotechgate subscribers only)	45.00	USA	30-Mar-16
Symbiomix	OrbiMed Fidelity BioSciences HBM Partners Square 1 Bank	41.00	USA	05-May-15
Iterum Therapeutics Ltd.	4 key investors (for Biotechgate subscribers only)	40.00	Ireland	18-Nov-15

Contact us for any enquires you have concerning the antibiotics investors and market or sign up for a demo here:

[http://www.biotechgate.com/web/cms/index.php/investor\\_database.html](http://www.biotechgate.com/web/cms/index.php/investor_database.html)

July 2017

For any comments or questions, please contact [Patrik Frei](#)